Literature DB >> 8592993

Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.

M Nakashima1, T Uematsu, K Kosuge, H Kusajima, T Ooie, Y Masuda, R Ishida, H Uchida.   

Abstract

The pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, was examined in healthy male volunteers after the oral administration of a single dose of 100, 200, 400, or 600 mg and multiple doses of 300 mg twice daily for 6.5 days (13 total doses). Throughout the whole study period, AM-1155 was well tolerated in every subject. In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively. The elimination half-life was 7 to 8 h, independently of the doses. The unchanged drug was excreted mainly in the urine, with 82 to 88% of the doses appearing for 72 h. The fecal recovery of the unchanged drug amounted to 5.7% for 72 h after a single oral administration of a 400-mg dose. Urinary excretion of metabolites was minimal. The serum protein binding was 20%, independently of the concentrations in serum. The concentrations in saliva were approximately 80% of those in serum. The intake of food had no effect on the pharmacokinetic parameters and urinary excretion of AM-1155 except the slight decrease in area under the concentration-time curve. The concurrent administration of probenecid prolonged the elimination half-life, increased the area under the concentration-time curve, and decreased the apparent total body clearance, renal clearance, urinary recovery of unchanged drug, and the excretion ratio (intrinsic renal clearance of AM-1155/creatinine clearance). This indicated that the tubular secretion contributed to the renal excretion of AM-1155. In the multiple-dose study, the concentrations of AM-1155 in serum and urine reached a steady state within 2 to 3 days. The measured concentrations in serum fitted well the simulation curve, which reflected the persistence of linear pharmacokinetics of AM-1155. In conclusion, AM-1155 is expected to be clinically useful because of its potent antibacterial activity and favorable pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592993      PMCID: PMC163003          DOI: 10.1128/AAC.39.12.2635

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Pharmacokinetics of temafloxacin in humans after single oral doses.

Authors:  G R Granneman; P Carpentier; P J Morrison; A G Pernet
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Pharmacokinetic aspects of newer quinolones.

Authors:  T Uematsu; M Nakashima
Journal:  Prog Drug Res       Date:  1992

3.  High-performance liquid chromatographic determination of 6,8-difluoro-1-(2-fluoroethyl)-1,4- dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid and its metabolites in laboratory animals.

Authors:  H Kusajima; T Ooie; F Kawahara; H Uchida
Journal:  J Chromatogr       Date:  1986-08-22

4.  Renal handling of fleroxacin in rabbits, dogs, and humans.

Authors:  K Shiba; A Saito; J Shimada; S Hori; M Kaji; T Miyahara; H Kusajima; S Kaneko; S Saito; T Ooie
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

5.  Pharmacokinetics and tissue penetration of orally administered lomefloxacin.

Authors:  J W Stone; J M Andrews; J P Ashby; D Griggs; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

6.  Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans.

Authors:  J Shimada; T Yamaji; Y Ueda; H Uchida; H Kusajima; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

7.  Crystalluria and ciprofloxacin, influence of urinary pH and hydration.

Authors:  S B Thorsteinsson; T Bergan; S Oddsdottir; R Rohwedder; R Holm
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

8.  In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.

Authors:  M Hosaka; T Yasue; H Fukuda; H Tomizawa; H Aoyama; K Hirai
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

9.  Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.

Authors:  M Nakashima; M Kanamaru; T Uematsu; A Takiguchi; A Mizuno; T Itaya; F Kawahara; T Ooie; S Saito; H Uchida
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

Review 10.  Pharmacokinetic disposition of quinolones in human body fluids and tissues.

Authors:  F Sörgel; U Jaehde; K Naber; U Stephan
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more
  43 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.

Authors:  S Lober; S Ziege; M Rau; G Schreiber; A Mignot; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers.

Authors:  H Stass; R Sachse
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Fluoroquinolone drug class update.

Authors:  A Bichsel; C W James; C Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-07

5.  Population pharmacokinetic model for gatifloxacin in pediatric patients.

Authors:  Christopher M Rubino; Edmund V Capparelli; John S Bradley; Jeffrey L Blumer; Gregory L Kearns; Michael Reed; Richard F Jacobs; Brenda Cirincione; Dennis M Grasela
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

Review 6.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Gatifloxacin efficacy in treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in rabbits.

Authors:  Mark E Shirtliff; Jason H Calhoun; Jon T Mader
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

8.  Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.

Authors:  Bruno Fantin; Xavier Duval; Laurent Massias; Loubna Alavoine; Françoise Chau; Sylvie Retout; Antoine Andremont; France Mentré
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

9.  Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 10.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.